Clinical Trials Directory

Trials / Completed

CompletedNCT00330967

Mechanisms of Insulin Resistance in Humans

Status
Completed
Phase
Study type
Observational
Enrollment
25 (actual)
Sponsor
US Department of Veterans Affairs · Federal
Sex
All
Age
21 Years – 65 Years
Healthy volunteers
Accepted

Summary

The Objectives of the study are to: (1)compare the inflammatory response and insulin resistance in skeletal muscles during a systemic infusion of lipid with that during a local infusion of lipid into the femoral artery. which would cause minimal or no systemic hyperlipidemia but local plasma free fatty acid (FFA) concentrations similar to those during the systemic lipid infusion, and (2) determine the inflammatory response and insulin resistance in skeletal muscle during an infusion of lipid into the femoral artery as described above after NF-KB inhibition by high dose salicylate treatment in humans.

Detailed description

Insulin resistance in skeletal muscle is a characteristic abnormality in obesity and the metabolic syndrome and a major factor responsible for the development of type 2 diabetes. Although the mechanisms responsible for muscle insulin resistance are largely unclear, lipid oversupply is an important factor. Among numerous potential mechanisms whereby lipid oversupply may cause muscle insulin resistance, current evidence points towards inflammation as being critical. Recent studies in animals, however, indicate that the inflammatory response in skeletal muscles may require the presence of circulating pro-inflammatory factors suggesting that the inflammation induced insulin resistance in skeletal muscles may be a secondary event. More specifically, activation of Nuclear Factor-Kappa B(NF-kB), and inflammatory master switch that drives the production of numerous pro-inflammatory cytokines in fat and liver, has been implicated in causing insulin resistance in skeletal muscles by increasing circulating pro-inflammatory cytokines. In contrast, animal studies have found that activation of NF-KB directly in skeletal muscles has no or little effect on its insulin sensitivity but does produce other abnormalities such as increased proteasome activity. The study shall therefore be undertaken to determine to what extent lipid-induced inflammation and insulin resistance in skeletal muscles requires the presence of circulating proinflammatory factors in humans.

Conditions

Interventions

TypeNameDescription
DRUG20% Intralipidlipid infusion

Timeline

Start date
2006-04-01
Primary completion
2012-01-01
Completion
2014-08-01
First posted
2006-05-29
Last updated
2015-04-03
Results posted
2015-03-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00330967. Inclusion in this directory is not an endorsement.